Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Sheffield United CEO Stephen Bettis has questioned the likelihood of any instant impact the Independent Football Regulator may be able to have on the ongoing crisis at Sheffield Wednesday. The Owls ...

The Writers Guild of America East is telling its CBS News members that the network assured them that they won’t face discipline if they decline to respond to new editor-in-chief Bari Weiss’ memo to ...

“I hope you are as excited as I am about the prospect of elevating CBS News to its rightful place as No. 1: the most trusted and most consumed news source in the nation,” Weiss wrote. “So, I’m ...

Last month, a Pew Research Center report shed light on Google's AI Overviews' effect on web publishing. In short, the analysis painted an abysmal outlook for anyone relying on web traffic. But on ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...